ATE452647T1 - Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide - Google Patents

Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide

Info

Publication number
ATE452647T1
ATE452647T1 AT01981902T AT01981902T ATE452647T1 AT E452647 T1 ATE452647 T1 AT E452647T1 AT 01981902 T AT01981902 T AT 01981902T AT 01981902 T AT01981902 T AT 01981902T AT E452647 T1 ATE452647 T1 AT E452647T1
Authority
AT
Austria
Prior art keywords
actin
sequestring
peptides
inhibiting
skin aging
Prior art date
Application number
AT01981902T
Other languages
English (en)
Inventor
Allan Goldstein
Original Assignee
Regenerx Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals filed Critical Regenerx Biopharmaceuticals
Application granted granted Critical
Publication of ATE452647T1 publication Critical patent/ATE452647T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01981902T 2000-11-02 2001-11-02 Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide ATE452647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24490100P 2000-11-02 2000-11-02
PCT/US2001/042900 WO2002036143A1 (en) 2000-11-02 2001-11-02 Inhibition or reversal of skin aging by actin-sequestering peptides

Publications (1)

Publication Number Publication Date
ATE452647T1 true ATE452647T1 (de) 2010-01-15

Family

ID=22924553

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981902T ATE452647T1 (de) 2000-11-02 2001-11-02 Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide

Country Status (10)

Country Link
EP (1) EP1335743B1 (de)
JP (2) JP4224297B2 (de)
AT (1) ATE452647T1 (de)
AU (2) AU2002213513B2 (de)
CA (1) CA2426200C (de)
DE (1) DE60140892D1 (de)
DK (1) DK1335743T3 (de)
ES (1) ES2338633T3 (de)
PT (1) PT1335743E (de)
WO (1) WO2002036143A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100529B2 (de) 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 stimuliert wundheilung
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
US8399609B2 (en) 2004-03-05 2013-03-19 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
MX2008001084A (es) * 2005-07-26 2008-03-11 Regenerx Biopharmaceuticals Composiciones para el tratamiento o prevencion del deterioro, lesion o dano de tejido debido a insuficiencia cardiaca congestiva.
CN105504043B (zh) * 2008-03-17 2020-01-31 雷金纳克斯生物制药公司 改进的β胸腺素片段
US9808654B2 (en) 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
KR102265430B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도
JP7123290B2 (ja) 2020-06-02 2022-08-22 三菱電機株式会社 ターボファン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP1100529B2 (de) * 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 stimuliert wundheilung

Also Published As

Publication number Publication date
AU1351302A (en) 2002-05-15
EP1335743A1 (de) 2003-08-20
EP1335743A4 (de) 2004-09-15
JP2009046502A (ja) 2009-03-05
DK1335743T3 (da) 2010-04-06
CA2426200C (en) 2014-08-19
DE60140892D1 (de) 2010-02-04
EP1335743B1 (de) 2009-12-23
JP4224297B2 (ja) 2009-02-12
AU2002213513B2 (en) 2006-05-25
WO2002036143A1 (en) 2002-05-10
CA2426200A1 (en) 2002-05-10
ES2338633T3 (es) 2010-05-11
PT1335743E (pt) 2010-03-29
JP2004527463A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
WO2003020215A3 (en) Methods of treating mycocardial event related coditions with thymosin beta 4
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DE3587286D1 (de) Antimikrobielle zusammensetzungen.
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
BR0111718A (pt) Peptìdeos quimicamente modificados, composições e métodos de produção e uso
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
TR199701484T1 (xx) Endoparazit �ld�r�c� bile�im.
DK1483290T3 (da) Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger
NO954722D0 (no) Peptid inhibitorer med urokinase reseptoraktivitet
ATE452647T1 (de) Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide
ES2188763T3 (es) Factor del tipo relaxina y metodos y usos del mismo.
ATE400294T1 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
AR015945A1 (es) Composiciones de spray para el cabello autofobicas
IT1212508B (it) Analoghi retro - invertiti dei penta - ed esapeptidi c - terminali della sostanza p. utili come vasodilatatori
ES2107124T3 (es) Procedimiento para inhibir la actividad de endotoxinas.
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
AR000357A1 (es) Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico
AR025660A1 (es) PRECURSOR DE HIRUDINA, PROCEDIMIENTO PAA LA PREPARACIoN DE LEU-HIRUDINA Y SU EMPLEO PARA LA PREPARACIoN DE LEU-HIRUDINA.
DE60034879T8 (de) Lantibiotikum
WO2002012326A3 (en) Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
ATE301194T1 (de) Beta-defensine
DE60031422D1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
ES2194744T3 (es) Derivados de quinocardina, su procedimiento de preparacion y su aplicacion como antifungicos.
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335743

Country of ref document: EP